Gain insights from our experts...
Optimizing lipid nanoparticles (LNPs) processing for siRNA delivery by microfluidics system
The success of mRNA vaccines during the COVID-19 pandemic has accelerated the advancement of nucleic acid delivery technologies. In addition to mRNA, interfering RNA offers potential to treat diseases beyond the reach of small molecules. However, therapeutic success hinges on efficient and targeted delivery systems. Lipid nanoparticles (LNPs), especially those produced via microfluidics, have emerged as a leading platform for RNA delivery. delivery. for RNA.
Join Dr. Qiaobin Hu as he explores LNP formulation for siRNA delivery using a microfluidic flow-focusing system.
Optimising lipid nanoparticles (LNPs) processing for siRNA delivery by microfluidics system
866.3 KB
Explore our poster presentation with Qiaobin Hu
Explore additional content
recent insights:
CPHI Milan: Reflecting on the conversations, growing connections and creating opportunities shaping Croda Pharma
CPHI Milan brought together the pharmaceutical industry to share ideas, explore new opportunities and discuss the challenges shaping the future of drug development and manufacturing.
What sustainability really means for pharmaceutical ingredients
Sustainability is not just an environmental consideration. In pharmaceuticals, patient supply and consistent quality should always be at the forefront. Sourcing ingredients from unstable, costly or...
A proven foundation: the history of aluminium adjuvants
Vaccine developers today have access to an expanding range of adjuvant technologies. However, aluminium-based adjuvants remain some of the most established and widely used ingredients for vaccine...